Format

Send to

Choose Destination
J Infect Dis. 2018 May 5;217(11):1770-1781. doi: 10.1093/infdis/jiy064.

Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone.

Author information

1
Department of Internal Medicine, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas.
2
Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
3
Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio.
4
Case Western Reserve University School of Medicine, Cleveland, Ohio.
5
Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
6
AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, Maryland.
7
Department of Pathology and Lab Medicine, University of California -Los Angeles (UCLA), Los Angeles, California.
8
HIV Research Branch, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
9
Social and Scientific Systems, Silver Spring, Maryland.
10
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
11
Vaccine Research Center, National Institutes of Health, Bethesda, Maryland.
12
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

Abstract

Background:

Fibrosis in lymph nodes may limit CD4+ T-cell recovery, and lymph node and adipose tissue fibrosis may contribute to inflammation and comorbidities despite antiretroviral therapy (ART). We hypothesized that the angiotensin receptor blocker and peroxisome proliferator-activated receptor γ agonist telmisartan would decrease lymph node or adipose tissue fibrosis in treated human immunodeficiency virus type 1 (HIV) infection.

Methods:

In this 48-week, randomized, controlled trial, adults continued HIV-suppressive ART and received telmisartan or no drug. Collagen I, fibronectin, and phosphorylated SMAD3 (pSMAD3) deposition in lymph nodes, as well as collagen I, collagen VI, and fibronectin deposition in adipose tissue, were quantified by immunohistochemical analysis at weeks 0 and 48. Two-sided rank sum and signed rank tests compared changes over 48 weeks.

Results:

Forty-four participants enrolled; 35 had paired adipose tissue specimens, and 29 had paired lymph node specimens. The median change overall in the percentage of the area throughout which collagen I was deposited was -2.6 percentage points (P = 0.08) in lymph node specimens and -1.3 percentage points (P = .001) in adipose tissue specimens, with no between-arm differences. In lymph node specimens, pSMAD3 deposition changed by -0.5 percentage points overall (P = .04), with no between-arm differences. Telmisartan attenuated increases in fibronectin deposition (P = .06). In adipose tissue, changes in collagen VI deposition (-1.0 percentage point; P = .001) and fibronectin deposition (-2.4 percentage points; P < .001) were observed, with no between-arm differences.

Conclusions:

In adults with treated HIV infection, lymph node and adipose tissue fibrosis decreased with continued ART alone, with no additional fibrosis reduction with telmisartan therapy.

PMID:
29401318
PMCID:
PMC5946950
[Available on 2019-05-05]
DOI:
10.1093/infdis/jiy064

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center